ArticleEuropean heart journal. Cardiovascular Imaging2021
Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
Article in European heart journal. Cardiovascular Imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Evaluating the predictive value of late gadolinium enhancement assessed by cardiac magnetic resonance on sudden cardiac death in patients selected for implantable cardioverter defibrillator and cardiac resynchronization therapy implantation: a systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Pooled it
- Enhancing risk prediction for sudden cardiac death: quantitative late gadolinium enhancement analysis in hypertrophic cardiomyopathy.Insights into imaging · 2026Article
- Imaging-Based Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Current Evidence and Clinical Perspectives.Medical sciences (Basel, Switzerland) · 2026Review
- Endomyocardial Gremlin-1 is associated with structural remodeling and adverse clinical outcomes in non-ischemic cardiomyopathy.Communications medicine · 2026Article
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
- A bibliometric and visual analysis of implantable cardioverter defibrillator use in hypertrophic cardiomyopathy: 2000-2025.Journal of cardiothoracic surgery · 2026Article
- ECG markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy.Open heart · 2025Article
- Late Gadolinium Enhancement and Electrocardiographic Associations in Hypertrophic Cardiomyopathy.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2025Article
- Incremental prognostic value of left atrial strain in apical hypertrophic cardiomyopathy: a cardiovascular magnetic resonance study.European radiology · 2025Article
- Exploring the Current Status of Risk Stratification in Hypertrophic Cardiomyopathy: From Risk Models to Promising Techniques.Journal of cardiovascular development and disease · 2025Review
- The Prognostic Implication of Late Gadolinium Enhancement Quantification and Syncope in Hypertrophic Cardiomyopathy.Journal of clinical medicine · 2025Article
- Developing a risk prediction model for sudden cardiac death in children with hypertrophic cardiomyopathy.Frontiers in pediatrics · 2025Article
- Cardiac magnetic resonance research advances in myocardial fibrosis of hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2025Review
- Exploratory study of serum protein biomarkers for sudden cardiac arrest using protein extension assay: A case-control study.PloS one · 2025Article
- [Clincial Research Progress in Using Magnetic Resonance Imaging to Assess Myocardial Fibrosis in Hypertrophic Cardiomyopathy].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Left ventricular fibrosis in arrhythmic mitral valve prolapse: quantification and comparison of semi-automated techniques assessed by cardiac magnetic resonance.The international journal of cardiovascular imaging · 2024Article
- Solving the Riddle of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: The Added Role of Cardiac Magnetic Resonance.Journal of cardiovascular development and disease · 2023Article
- Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy.Journal of clinical medicine · 2023Review
- Manganese-Enhanced Magnetic Resonance Imaging of the Heart.Journal of magnetic resonance imaging : JMRI · 2023Review
- Repeatability and reproducibility of cardiac manganese-enhanced magnetic resonance imaging.Scientific reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSudden cardiac death (SCD) is an appalling complication of hypertrophic cardiomyopathy (HCM). There is an ongoing discussion about the optimal SCD risk stratification strategy since established SCD risk models have suboptimal discriminative power. The aim of this study was to evaluate the prognostic value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for SCD risk stratification compared to the European Society of Cardiology (ESC) SCD risk score and traditional risk factors in an >10-year follow-up. METHODS AND
resultsTwo hundred and twenty consecutive patients with HCM and LGE-CMR were enrolled. Follow-up data were available in 203 patients (median age 58 years, 61% male) after a median follow-up period of 10.4 years. LGE was present in 70% of patients with a median LGE amount of 1.6%, the median ESC 5-year SCD risk score was 1.84. In the overall cohort, SCD rates were 2.3% at 5 years, 4.8% at 10 years, and 15.7% at 15 years, independent from established risk models. An LGE amount of >5% left ventricular (LV) mass portends the highest risk for SCD with SCD prevalences of 5.5% at 5 years, 13.0% at 10 years, and 33.3% at 15 years. Conversely, patients with no or ≤5% LGE of LV mass have favourable prognosis.
conclusionsLGE-CMR in HCM patients allows effective 10-year SCD risk stratification beyond established risk factors. LGE amount might be added to established risk models to improve its discriminatory power. Specifically, patients with >5% LGE should be carefully monitored and might be adequate candidates for primary prevention implantable cardioverter-defibrillator during the clinical long-term course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.